Enanta Pharmaceuticals, Inc.
ENTA
$8.53
-$0.12-1.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.22% | 26.81% | 24.10% | 13.28% | 12.67% |
| Total Depreciation and Amortization | 49.68% | 22.53% | 3.24% | -1.48% | 7.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.45% | 9.81% | 2.28% | 37.24% | -31.99% |
| Change in Net Operating Assets | 946.69% | 5,578.23% | -58.15% | -11.14% | -19.30% |
| Cash from Operations | 74.23% | 48.32% | 23.70% | 23.64% | 7.33% |
| Capital Expenditure | -96.71% | -348.21% | -287.29% | -98.15% | -13.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.32% | 226.21% | 277.57% | 271.12% | 318.72% |
| Cash from Investing | 12.01% | 187.40% | 239.89% | 208.69% | 237.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 105.06% | -24.30% | -77.73% | -93.34% | -98.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.16% | -113.95% | -113.47% | -114.18% | -110.47% |
| Cash from Financing | -24.85% | -113.83% | -113.26% | -113.94% | -110.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.19% | 59.14% | 2,039.56% | -216.33% | -188.91% |